Eiichi Sasaki
YOU?
Author Swipe
View article: Supplementary Figure 5 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 5 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 5. Recovery of MET protein levels by inhibition of MET/HGF signaling.
View article: Data from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Data from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI), benefits survival of patients with non–small cell lung cancer (NSCLC) who harbor activating EGFR mutations. However, elevated expression of hepatocy…
View article: Supplementary Figure 3 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 3 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 3. In vivo efficacy of onartuzumab combined with erlotinib in tumors harboring an activating EGFR mutation and with a high level of HGF expression.
View article: Supplementary Figure 7 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 7 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 7. Comparison of MET protein levels in HGF-autocrine cell lines with those in representative standard cell lines for MET-IHC scoring.
View article: Supplementary Figure 2 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 2 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 2. Characteristics of HGF-overexpressing clones in PC-9 and HCC827 cells.
View article: Supplementary Figure 5 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 5 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 5. Recovery of MET protein levels by inhibition of MET/HGF signaling.
View article: Supplementary Figure 4 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 4 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 4. Representative images of MET-IHC scoring 0, +1, +2, +3.
View article: Supplementary Figure 2 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 2 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 2. Characteristics of HGF-overexpressing clones in PC-9 and HCC827 cells.
View article: Supplementary Figure 6 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 6 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 6. Recovery of MET protein levels by inhibition of MET/HGF signaling in HCC2108, a lung adenocarcinoma cell line.
View article: Supplementary Figure 1 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 1 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 1. HGF attenuates sensitivity to erlotinib in HCC827 cells.
View article: Supplementary Information from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Information from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Information
View article: Data from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Data from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Erlotinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR-TKI), benefits survival of patients with non–small cell lung cancer (NSCLC) who harbor activating EGFR mutations. However, elevated expression of hepatocy…
View article: Supplementary Figure 3 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 3 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 3. In vivo efficacy of onartuzumab combined with erlotinib in tumors harboring an activating EGFR mutation and with a high level of HGF expression.
View article: Supplementary Figure 7 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 7 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 7. Comparison of MET protein levels in HGF-autocrine cell lines with those in representative standard cell lines for MET-IHC scoring.
View article: Supplementary Figure 1 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 1 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 1. HGF attenuates sensitivity to erlotinib in HCC827 cells.
View article: Supplementary Information from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Information from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Information
View article: Supplementary Figure 6 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 6 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 6. Recovery of MET protein levels by inhibition of MET/HGF signaling in HCC2108, a lung adenocarcinoma cell line.
View article: Supplementary Figure 4 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression
Supplementary Figure 4 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating <i>EGFR</i> Mutations and HGF Overexpression Open
Supplementary Figure 4. Representative images of MET-IHC scoring 0, +1, +2, +3.
View article: Biological difference between L858R and exon 19 deletion contributes to recurrence-free survival of resected non-small cell lung cancer
Biological difference between L858R and exon 19 deletion contributes to recurrence-free survival of resected non-small cell lung cancer Open
Background:The differences in biological characteristics among different genotypes of classical EGFR mutations have not been clarified. This study aims to clarify the clinical and biological differences between L858R and 19 deletion in NSC…
View article: CONSTRUCTION OF REMAINING AXIAL FORCE EVALUATION METHOD BASED ON EDDY CURRENT MEASUREMENT
CONSTRUCTION OF REMAINING AXIAL FORCE EVALUATION METHOD BASED ON EDDY CURRENT MEASUREMENT Open
高力ボルト摩擦接合において近年,ボルト軸力の低下等の変動が指摘され問題となっている.本研究では高力ボルト残存軸力を非破壊で簡便に評価すべく,渦電流計測に基づく残存軸力評価手法について実験と数値シミュレーションとの両面から検討した.渦電流計測では鋼部材の透磁率と応力の関係を用いて応力状態変化を取得可能であることから,ボルト頭部の応力状態に着目し,ボルト頭部に渦電流プローブを設置するだけで軸力を評価可能な新たな手法の構築を目的として検討を行った.また,軸力によりボルト頭部が変形…
View article: A STUDY ON ULTRASONIC MEASUREMENT OF COATING THICKNESS ON BACKSIDE OF STEEL PLATE AND THE FAYING SURFACE IN HIGH-STRENGTH BOLTED FRICTION JOINTS WITH MACHINE LEARNING
A STUDY ON ULTRASONIC MEASUREMENT OF COATING THICKNESS ON BACKSIDE OF STEEL PLATE AND THE FAYING SURFACE IN HIGH-STRENGTH BOLTED FRICTION JOINTS WITH MACHINE LEARNING Open
近年,防食等のため,接合面に無機ジンクリッチペイントを塗布した高力ボルト摩擦接合継手が適用されることが多くなっており,すべり係数に接合面塗膜厚さが影響することが明らかとなっている.供用中のボルト継手において,接合面塗膜厚さを非解体のまま計測できれば,現在の接合面塗膜厚さとすべり係数の規定に基づき,ボルト継手耐力を再評価できる可能性がある.さらに,接合後に塗膜厚さが変化する接触圧の大きい領域の計測も可能となれば,ボルト継手における耐荷性能のメカニズムの議論などに有益な情報とな…
View article: ULTRASONIC HIGH-STRENGTH BOLT AXIAL FORCE EVALUATION BY MACHINE LEARNING-BASED TO WAVEFORM ANALYSIS
ULTRASONIC HIGH-STRENGTH BOLT AXIAL FORCE EVALUATION BY MACHINE LEARNING-BASED TO WAVEFORM ANALYSIS Open
高力ボルト接合のボルト軸力は供用中に様々な影響で低下する場合があり,接合の現有性能把握の上で,ボルト軸力を評価することは重要である.これまで,既設ボルトの軸力計測手法は複数提案されているが,評価精度や適用性の面で改善の余地がある.本研究では超音波計測による方法に着目し,まず得られた波形にランダムフォレストを用いた機械学習を適用することで,超音波計測波形の初期時間帯にボルト軸力と関連する情報が含まれる可能性を確認した.さらに評価精度向上のため,ボルト軸力と関連する区間を選定し…
View article: Experimental and numerical analysis of the behavior of corroded steel plates strengthened with thin-ply glass/carbon hybrid FRP composites
Experimental and numerical analysis of the behavior of corroded steel plates strengthened with thin-ply glass/carbon hybrid FRP composites Open
An experimental and numerical study on the behavior of strengthening corroded steel plates using stepped ends of thin-ply hybrid FRP composites is carried out. The results showed that the hybrid strengthening of corroded steel plates mainl…
View article: Bifurcation structure of unstable periodic orbits in plane Couette flow with the Smagorinsky model
Bifurcation structure of unstable periodic orbits in plane Couette flow with the Smagorinsky model Open
In order to obtain insights into dynamics of developed plane Couette turbulence, this paper considers bifurcation structure of unstable periodic orbits (UPOs) in the large-eddy-simulation (LES) system with the Smagorinsky-type eddy viscosi…
View article: Evaluation of Eddy Current Response Due to the Applied Stress on a Steel Plate Using Phase Diagram
Evaluation of Eddy Current Response Due to the Applied Stress on a Steel Plate Using Phase Diagram Open
Structural health monitoring of steel structures is crucial for inspection of corrosion and cracking in structural members, compromising their safety and serviceability. In the present study, the prospective of evaluation of change in stre…